Please see the Genome BC news release from last week. Augurex is proud of and appreciates the ongoing support that we receive from provincial and federal government programs to expedite JOINTstat™ access to patients worldwide. Augurex is recognized as an emerging biotechnology company that is transforming patient care and contributing to Canada’s leadership role in the global knowledge economy.
NEWS RELEASE | JANUARY 25, 2017
GENOME BC INVESTS IN AUGUREX, A COMPANY TRANSFORMING HEALTH MANAGEMENT AND OUTCOMES FOR PATIENTS WITH AUTOIMMUNE DISEASES AFFECTING JOINTS
Vancouver, BC — Genome BC is pleased to announce its investment in Augurex Life Sciences Corp., through its Industry Innovation (I²) Program. Augurex is a biotechnology company transforming disease management and health outcomes for patients with autoimmune diseases affecting joints such as rheumatoid arthritis (RA).
Augurex has developed its first blood test, called JOINTstat™, which measures the 14-3-3η protein in blood for early RA diagnosis and joint damage risk monitoring. JOINTstat also predicts RA development in people with joint pain. Since 14-3-3η is a very early contributor to disease and correlates with joint damage prognosis, it facilitates the identification of patients for early RA intervention and tighter control of treatment so that clinical and remission targets can be reached; the highest priorities in rheumatology care. Read Full Article